VeroScience is committed to developing novel, practical, and effective therapies for chronic debilitating human diseases such as Type 2 diabetes, metabolic syndrome, autoimmune disease, and cancer through interdisciplinary basic research. VeroScience researchers study biological clocks in vertebrates and their organizational influence on neuroendocrine regulation of physiology to develop new treatment strategies for metabolic and immune disorders. By investigating and mimicking nature’s means of regulating biochemical physiology for survival of vertebrates in the wild, VeroScience develops treatment strategies, not products per se, aimed at re-directing pathological biochemistry back towards its “normal” physiological organization. A major platform technology of the company is Circadian Neuroendocrine Resetting Therapy® that is utilized as a generator of multiple therapeutic strategies to treat a variety of disease states. The circadian timed daily (morning) administration of Cycloset®, a quick release formulation of bromocriptine mesylate (bromocriptine-QR), a dopamine agonist, was developed for the treatment of type 2 diabetes. Cycloset is approved by the U.S. FDA, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.